BDBM50110178 CHEMBL3603847::US10787436, Compound I-23

SMILES CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1

InChI Key InChIKey=OBJNFLYHUXWUPF-UHFFFAOYSA-N

Data  1 KI  38 IC50  1 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 40 hits for monomerid = 50110178   

TargetMitogen-activated protein kinase 8(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 550nMAssay Description:In vitro kinase assays with immunoprecipitated proteins (or recombinant CAK complexes) were performed as follows. Kinase reactions were performed in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/9/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 1.00E+3nMAssay Description:In vitro kinase assays with immunoprecipitated proteins (or recombinant CAK complexes) were performed as follows. Kinase reactions were performed in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/9/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 550nMAssay Description:In vitro kinase assays with immunoprecipitated proteins (or recombinant CAK complexes) were performed as follows. Kinase reactions were performed in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/9/2021
Entry Details
Go to US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 550nMAssay Description:In vitro kinase assays with immunoprecipitated proteins (or recombinant CAK complexes) were performed as follows. Kinase reactions were performed in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/9/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 550nMAssay Description:In vitro kinase assays with immunoprecipitated proteins (or recombinant CAK complexes) were performed as follows. Kinase reactions were performed in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/9/2021
Entry Details
Go to US Patent

TargetCyclin-C/Cyclin-dependent kinase 8(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 1.00E+3nMAssay Description:In vitro kinase assays with immunoprecipitated proteins (or recombinant CAK complexes) were performed as follows. Kinase reactions were performed in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/9/2021
Entry Details
Go to US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 550nMAssay Description:In vitro kinase assays with immunoprecipitated proteins (or recombinant CAK complexes) were performed as follows. Kinase reactions were performed in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/9/2021
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase kinase kinase 11(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 550nMAssay Description:In vitro kinase assays with immunoprecipitated proteins (or recombinant CAK complexes) were performed as follows. Kinase reactions were performed in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/9/2021
Entry Details
Go to US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 1.00E+3nMAssay Description:In vitro kinase assays with immunoprecipitated proteins (or recombinant CAK complexes) were performed as follows. Kinase reactions were performed in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/9/2021
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 1(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 100nMAssay Description:In vitro kinase assays with immunoprecipitated proteins (or recombinant CAK complexes) were performed as follows. Kinase reactions were performed in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/9/2021
Entry Details
Go to US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 1.00E+3nMAssay Description:In vitro kinase assays with immunoprecipitated proteins (or recombinant CAK complexes) were performed as follows. Kinase reactions were performed in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/9/2021
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 9(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 550nMAssay Description:In vitro kinase assays with immunoprecipitated proteins (or recombinant CAK complexes) were performed as follows. Kinase reactions were performed in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/9/2021
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase kinase kinase 11(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 100nMAssay Description:In vitro kinase assays with immunoprecipitated proteins (or recombinant CAK complexes) were performed as follows. Kinase reactions were performed in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/9/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 12(Human)
Istituto Italiano Di Tecnologia

Curated by ChEMBL
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 864nMAssay Description:Inhibition of CDK12 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2022
Entry Details Article
PubMed
TargetCyclin-dependent kinase 13(Human)
Istituto Italiano Di Tecnologia

Curated by ChEMBL
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 225nMAssay Description:Inhibition of CDK13 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2022
Entry Details Article
PubMed
TargetCyclin-dependent kinase 7(Human)
Istituto Italiano Di Tecnologia

Curated by ChEMBL
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 3.20nMAssay Description:Inhibition of human CDK7 incubated for 180 mins by LanthaScreen Eu Kinase binding assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2022
Entry Details Article
PubMed
TargetCyclin-dependent kinase 7(Human)
Istituto Italiano Di Tecnologia

Curated by ChEMBL
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 3.20nMAssay Description:Inhibition of CDK7 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/23/2023
Entry Details
PubMed
TargetCyclin-dependent kinase 7(Human)
Istituto Italiano Di Tecnologia

Curated by ChEMBL
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 240nMAssay Description:Inhibition of CDK7 (unknown origin) in human HAP1 cells incubated for 6 hrs by Western blot based competitive pull down assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2023
Entry Details
PubMed
TargetCyclin-dependent kinase 7(Human)
Istituto Italiano Di Tecnologia

Curated by ChEMBL
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 22nMAssay Description:Inhibition of CDK7 (unknown origin) assessed as phosphorylation of ULight 4EBP1 peptide substrate measured after 2 hrs by FRET-based LANCE Ultra KinS...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/20/2024
Entry Details
PubMed
TargetCyclin-dependent kinase 2(Human)
Shenyang Pharmaceutical University

Curated by ChEMBL
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of CDK2 (unknown origin) assessed as phosphorylation of ULight 4EBP1 peptide substrate measured after 2 hrs by FRET-based LANCE Ultra KinS...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/20/2024
Entry Details
PubMed
TargetCyclin-dependent kinase 13/Cyclin-K(Human)
Eli Lilly

Curated by ChEMBL
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 628nMAssay Description:Competitive irreversible inhibition of CDK13/cyclinK (unknown origin) in presence of 1 mM ATPMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/25/2021
Entry Details Article
PubMed
TargetCyclin-dependent kinase 7(Human)
Istituto Italiano Di Tecnologia

Curated by ChEMBL
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 27nMAssay Description:Inhibition of CDK7 (unknown origin) after 4 hrsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/25/2021
Entry Details Article
PubMed
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 1.00E+3nMAssay Description:Competitive irreversible inhibition of CDK7/cyclinH/MAT1 (unknown origin) using 5-FAM YSPTSPSYSPTSPSYSPTSPSKKKK as substrate in presence of 2 mM ATPMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/25/2021
Entry Details Article
PubMed
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 421nMAssay Description:Competitive irreversible inhibition of CDK7/cyclinH/MAT1 (unknown origin) using 5-FAM YSPTSPSYSPTSPSYSPTSPSKKKK as substrate in presence of Km ATPMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/25/2021
Entry Details Article
PubMed
TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 2.83E+3nMAssay Description:Competitive irreversible inhibition of CDK9/cyclin T (unknown origin) in presence of Km ATPMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/25/2021
Entry Details Article
PubMed
TargetCyclin-dependent kinase 12(Human)
Istituto Italiano Di Tecnologia

Curated by ChEMBL
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 371nMAssay Description:Competitive irreversible inhibition of CDK12/cyclinK (unknown origin) in presence of Km ATPMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/25/2021
Entry Details Article
PubMed
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 238nMAssay Description:Competitive irreversible inhibition of CDK7/cyclinH/MAT1 (unknown origin) in presence of 1 mM ATPMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/25/2021
Entry Details Article
PubMed
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataEC50:  10nMAssay Description:Competitive irreversible inhibition of CDK7/cyclinH/MAT1 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/25/2021
Entry Details Article
PubMed
TargetCyclin-dependent kinase 12(Human)
Istituto Italiano Di Tecnologia

Curated by ChEMBL
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 893nMAssay Description:Competitive irreversible inhibition of CDK12/cyclinK (unknown origin) in presence of 1 mM ATPMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/25/2021
Entry Details Article
PubMed
TargetCyclin-dependent kinase 7(Human)
Istituto Italiano Di Tecnologia

Curated by ChEMBL
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 3.20nMAssay Description:Competitive inhibition of human CDK7 in presence of ATPMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/16/2016
Entry Details Article
PubMed
TargetCyclin-dependent kinase 12(Human)
Istituto Italiano Di Tecnologia

Curated by ChEMBL
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 893nMAssay Description:Inhibition of CDK12 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2021
Entry Details Article
PubMed
TargetCyclin-dependent kinase 13(Human)
Istituto Italiano Di Tecnologia

Curated by ChEMBL
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 628nMAssay Description:Inhibition of CDK13 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2021
Entry Details Article
PubMed
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 238nMAssay Description:Inhibition of CDK7/cyclin H/MNAT1 (unknown origin) pre incubated up to 60 mins followed by substrate and ATP additionMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2021
Entry Details Article
PubMed
TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 11.3nMAssay Description:In vitro kinase assays with immunoprecipitated proteins (or recombinant CAK complexes) were performed as follows. Kinase reactions were performed in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/9/2021
Entry Details
Go to US Patent

TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 33.5nMAssay Description:In vitro kinase assays with immunoprecipitated proteins (or recombinant CAK complexes) were performed as follows. Kinase reactions were performed in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/9/2021
Entry Details
Go to US Patent

TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 201nMAssay Description:In vitro kinase assays with immunoprecipitated proteins (or recombinant CAK complexes) were performed as follows. Kinase reactions were performed in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/9/2021
Entry Details
Go to US Patent

TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 100nMAssay Description:In vitro kinase assays with immunoprecipitated proteins (or recombinant CAK complexes) were performed as follows. Kinase reactions were performed in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/9/2021
Entry Details
Go to US Patent

TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 100nMAssay Description:In vitro kinase assays with immunoprecipitated proteins (or recombinant CAK complexes) were performed as follows. Kinase reactions were performed in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/9/2021
Entry Details
Go to US Patent

TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataIC50: 550nMAssay Description:In vitro kinase assays with immunoprecipitated proteins (or recombinant CAK complexes) were performed as follows. Kinase reactions were performed in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/9/2021
Entry Details
Go to US Patent

LigandPNGBDBM50110178(CHEMBL3603847 | US10787436, Compound I-23)
Affinity DataKi:  255nMAssay Description:Competitive irreversible inhibition of CDK7/cyclinH/MAT1 (unknown origin) using 5-FAM YSPTSPSYSPTSPSYSPTSPSKKKK as substrateMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/25/2021
Entry Details Article
PubMed